Thus, HXEX-ALL1 may be a valuable cell model for further investigation on the mechanisms and potential targeted therapy of relapsed/refractory ALL, particularly for those developed a dominantly resistant to Asp. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.